Fundraising FoxIlab
1 known investors
Find your way into Ilab
Sign up to see every warm intro you have to Ilab
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ilab team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
South Korean drug developer working on small-molecule therapies for cancer, inflammation and immune disorders.
Also known as iLab Co., Ltd
Investors · 1
Company profile
researched Aug 2026iLab Co., Ltd is a South Korea-based pharmaceutical company, listed with a 2017 establishment year and a location in Gyeonggi-do, that develops small-molecule drug candidates. Its disclosed pipeline spans oncology, inflammatory and immune-system indications, with programs directed at targets including TNF-alpha, PD-L1, CSF-1R, IL-6 and a CSF-2R x PD-L1 combination.
The company is classified as a holding company and is recorded as both originator and active organization for its candidates, indicating in-house origination of its programs. Its most advanced asset, IA-14069, an oral TNF-alpha inhibitor for rheumatoid arthritis, has reached Phase 1. Other assets are at preclinical (IA-05592, a PD-L1 inhibitor for neoplasms) or discovery stage (CSF-1R and CSF-2R x PD-L1 oncology projects, and an IL-6-directed anti-inflammatory project).
Traction
Two Phase 1 studies of IA-14069 are recorded with iLab as sponsor: a first-in-human, double-blind, placebo-controlled single ascending dose study in healthy male subjects (NCT05317741, started 23 Aug 2021, completed), and a randomized, double-blind, placebo-controlled multiple ascending dose study in healthy subjects and rheumatoid arthritis patients including a methotrexate drug-drug interaction extension and preliminary efficacy assessment (NCT05533372, started 10 Oct 2022, recruiting). The pipeline comprises one Phase 1, one preclinical and three discovery-stage programs.
Latest developments
In November 2025, the British Journal of Pharmacology published a study on IA-0130, an oxindole-derivative gp130 binder, reporting inhibition of IL-6/gp130/STAT3 signalling and anticancer activity in ovarian cancer models, including anticancer drug-resistant lines.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Clinical-stage small-molecule developer whose lead program has completed a first-in-human study and entered multiple ascending dose testing, with remaining assets at preclinical and discovery stages.
Technology
iLab focuses on small-molecule drug discovery. Programs target TNF-alpha (TNF-alpha inhibition), PD-L1 (PD-L1 inhibition), CSF-1R, IL-6 and a dual CSF-2R x PD-L1 mechanism (CSF-2R antagonism). Related published research describes IA-0130, a 3-(1,3-diarylallylidene)oxindole derivative selected from 24 synthesised analogues for its binding to gp130, which inhibited gp130/STAT3 phosphorylation and suppressed growth, migration, invasion and metastasis in ovarian cancer and drug-resistant ovarian cancer cell lines, and delayed tumour growth after oral administration in a human ovarian cancer mouse xenograft model.
Go-to-market
Patients with rheumatoid arthritis, ovarian and other neoplasms, and inflammatory and immune-system diseases, addressed through pharmaceutical development.
Geography
Headquartered in Gyeonggi-do, South Korea.
History
Company records list 2017 as the founding year. First-in-human dosing of lead candidate IA-14069 began in August 2021, followed by a multiple ascending dose Phase 1 study starting in October 2022.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsBritish Journal of Pharmacology article reporting that IA-0130, a 3-(1,3-diarylallylidene)oxindole derivative, binds gp130, inhibits IL-6/gp130/STAT3 signalling and suppresses ovarian cancer growth and metastasis in vitro and in a mouse xenograft model.
Randomized, double-blind, placebo-controlled multiple ascending dose study in healthy subjects and in rheumatoid arthritis patients on stable methotrexate, including a drug-drug interaction extension and preliminary efficacy assessment; listed as recruiting.
Double-blind, placebo-controlled single ascending dose study evaluating safety, tolerability, pharmacokinetics, food effect and pharmacodynamics of a single oral dose of IA-14069 in healthy male subjects; listed as completed.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 7
primary sources listed
- ilabcorp.co.krilabcorp.co.kr · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Ilab do?
- South Korean drug developer working on small-molecule therapies for cancer, inflammation and immune disorders.
- Who are Ilab's investors?
- Ilab's investors include Atinum Investment Co. Ltd..